[24]
In the absence of special circumstances, and barring a special rule such as the former rule 1618, costs should follow the event. I am satisfied that no special reason exists to vary from that general principle. In the result, Novopharm having been successful on this application, will be entitled to its costs as against Merck. There will be no order as to costs with respect to the Minister.